Original Research Paper

Volume - 15 | Issue - 10 | October - 2025 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar

Neuro Sciences

IMPACT OF OPERTUNISTIC INFECTIONS IN THE OPERATION THEATRE: RECENT ADVANCES IN CARDIOVASCULAR AND THORACIC SURGERY UNIT

Dr. Monika Behera Senior Resident in Cardio Thoracic and Neuro Sciences Centre, All India Institute of Medical Sciences, New Delhi-110029, India

ABSTRACT **Background:** Surgical Site Infections (SSIs) is a serious public health burden in the World. SSI very common postoperative of complications. It occurs anywhere in the body, including the site of the incision. In this surgically operated organs or tissues, other locations were surgical instruments and placed safely. **Material And Methods:** A single-centre prospective epidemiological study was conducted (2022-2025). We enrolling patients admitted consecutively for transcatheter aortic valve implantation procedures. We are trying to find out the responsible pathogens. It obtained from the community or hospital based on the available opportunistic endogenous bacterial infections. Those were cause Surgical Site Infections (SSIs) by contaminating surgical wounds or implanted medical devices. The majority of cutaneous samples were obtained from each patient through properway. In the puncture site of the transcatheter aortic valve implantation procedure performed with before and after the skin detersion, from operator hands after skin detersion. **Results:** SSIs impacts were noted as (0.5% to 3.8%) of surgical patients. When compared with patients without SSIs, The rates of SSI higher, even though many laws and standards have been put in place to avoid these infections. The rate of infections now increased (3.5-1.5%) visible in naked eye. **Conclusion:** Therefore, morbidity and mortality were developed in the healthcare system at risk now. In detailed with brief information about the incidence, microbiology, preventive strategies and management of these infections were described clearly as per the original observations in our hospital set up including with antimicrobial Resistance. Need to understand these progressions.

KEYWORDS : SSI, Wound infection, Surgical site infections, Post-operative Infections, Antimicrobial Resistance, Research and development (R&D).

INTRODUCTION:

The Surgical site infection (SSI) infection that appears at the site of the incision were closing by up to 30 days for up to a year following implant surgery [1]. In 1992, the US Centers for Disease Control and Prevention (CDC) coined the term "SSI" as Surgical site infection (SSI) infection[1-2]. SSIs divided into three classes in accordance with definitions provided by the CDC & National Healthcare Safety Network (NHSN) [1-3]. Particularly, C Superficial incisional affects the subcutaneous tissues and skin C Deep incisional are very important [4]. In the deeper tissues unlike fascia and muscle C Organ infections that affect any part of the body [4-5]. An operative site Incidence are the most prevalent healthcare-associated infections (HAIs) is SSI [5-6].It accounts for (29-35%) of admitted patients and (38-40%) of patients in surgical wards and making it the second cause of HAI [3-6]. According to the CDC reports annual rate of surgical procedures are quite higher [5-7]. The incision are approximately (0.5% to 3-4% of surgical patients) will getting SSI infections near site [7-8] Preventive strategies in disinfection with chloramine-T did not effectively reduce on the non-tuberculous mycobacteria colonization of Maquet devices are need to improve now [7-8-9].

There are no cases reported as postoperative invasive infections (POIIFS) are linked with the Maquet devices [6-10]. Microbiological data emphasized that designing changes need to increase safety of devices. In researching find out developing new disinfection protocols [11]. It is including with Infective endocarditis severe complication arises following transcatheter aortic valve implantation [10-12].

MATERIAL AND METHODS:

Study Design: A single-centre prospective epidemiological study

Data Collection: A single-centre prospective epidemiological study was conducted (2022-2025).

Selection Criteria: We enrolling patients admitted consecutively for transcatheter aortic valve implantation procedures.

Methods:

We are trying to find out the responsible pathogens. It obtained from the community or hospital based on the available opportunistic endogenous bacterial infections. Those were cause Surgical Site Infections (SSIs) by contaminating surgical wounds or implanted medical devices observed closely. The majority of cutaneous samples were obtained from each patient through properway. In the puncture site of the transcatheter aortic valve implantation procedure performed with before and after the skin detersion, from operator hands after skin detersion located clearly.

RESULTS:

One hundred fifty patients with mean age of 85 ± 7.2 years, including with male-to-female ratio of 0.45. A mean value of body mass index (BMI) is obtained as 27 ± 4.8 kg/m^2. Before the skin detersion, enterococci (n = 52, 25%, 95% (CI) 10–35%), *Staphylococcus aureus* (n =52 (3.5%, 95% (CI) 1–15%) and Enterobacteriaceae (n = 46, 6%, 95% (CI) 2–15%). In cutaneous samples had positive in 52 patients and coagulase-negative staphylococci (n = 46, 85%, 95% CI (75–9%%) observed.

DISCUSSION:

As endocarditis incidence are rising day by day infections were remains a challenging condition including with different pathogens [16-18]. SSIs with major mechanisms and their associated infections were needed to be observed carefully [17-18-19-20]. Although, diversified microorganisms that cause infective SSIs and endocarditis. Several predisposing cardiac Critical conditions that present in the clinic [20]. Specific pathogen attributes interactions with the immune system [21-22]. It would lead to idiosyncratic diseases and their mechanisms and pathways cellular level [21-21-23]. As formation of vegetations, manifestation of infective endocarditis and SSIs are very different [19-22-23]. It appears to utilize relevant information to understanding cardiac tissue damage, distant embolism [23]. Endocardial surface of the heart, valves, together exposure in to an invasive pathogen under the right conditions clinically [23-24]. An opportunistic commensal, leads coordinated response from endothelial cells and their innate immune system, prothrombotic pathways respectively [25].

These responses contain the infection, but they also sustain it and render it indolent undoubtedly [20-26].Recent proteomic, imaging, and biochemical studies, hallmarks of an infected, consolidated thrombus clinically [25-27]. In vegetations extensive proteolytic activity (EPA) promoted growth and contribute into local tissue destruction for fragility and embolism [26-28]. The immune response, its abnormalities diagnostic possibilities is a key point in the management of patients with various diseases [29]. In infectious forms into oncological aspects several infections were associated [29-30]. We analyzed the data presented witin the current immune disorders and the possibility of their laboratory diagnostics in combination with clinical manifestations with special attention as an important [30-31].

We have performed in international databases over the last ten years respectfully [30-32]. We have represented our data on the possibility of diagnosing immunopathological processes due to changes in immune cells and soluble molecules in the cellular levels [30-31-32-33]. It is involved within the pathogenesis of a wide range of diseases for determination of antibodies and to detect autoimmune processes in the human body [34]. Laboratory techniques unlike PCR, RT-PCR, flow cytometry, ELISA, most clinical laboratories tests we were required to know worldwide infection types and their mechanisms systematically [30-35].

The diversity of pathogens accumulated knowledge, that the pathogenesis of the vast majority of environmental health and immune-mediated diseases is not yet known [35-36-37].The current success in dividing out immune-mediated diseases into distinct clusters [38]. It is totally based on the different types of inflammatory responses and different molecular mechanisms [35-36-37-38]. The involvement of different populations of T helper cells and cytokine molecules were represented all their significant progress and persistent [39]. Further research in this direction seems to be very promising, as it allows the newly developed identification with of new target cells and target molecules for both infectious and non infectious diseases. It is improved with more accuracy of diagnostics and targeted therapies [40]. In Abdominal aortic aneurysms (AAAs) also typically progress and insidiously and remain asymptomatic, until rupture, posing with substantial risk of fatal outcomes also associated with COVID infections respectively well defined by Prof. Mayadhar Barik, AIIMS, New Delhi-110029, India [40-171].

CONCLUSION:

These newly discovered findings support the amoxicillin-clavulanate as an important antibiotic prophylaxis before transcatheter aortic valve implantation.This new procedures to mitigate the risk of infective endocarditis and SSIs are associated with enterococcal colonization as an risk of mortality and morbidity. Need more research work to know better.

REFERENCES:

1. Leivaditis V, Maniatopoulos AA, Lausberg H, Mulita F, Papatriantafyllou A, Liolis E, Beltsios E, Adamou A, Kontodimopoulos N, Dahm M. Artificial Intelligence in Thoracic Surgery: A Review Bridging Innovation and Clinical Practice for the Next Generation of Surgical Care. Journal of Clinical Medicine. 2025 Apr 16;14(8):2729.
2. Ditommaso S, Garlasco J, Memoli G, Curtoni A, Bondi A, Ceccarelli A, Giacomuzzi M. Emergence of Mycobacterium gordonae in heater–cooler units: a five-year prospective surveillance of devices frequently subjected to chloramine-T booster disinfection. Journal of Hospital Infection. 2025 Jan 1;155:9-16.
3. Lourtet-Hascoët J, Van Rothem J, Combes N, Honton B, Hascoët S, Galinier JL, Fontenel B, Charbonneau H, Bonnet E. Transcatheter aortic valve implantation: Association between skin flora and infective endocarditis?. Archives of Cardiovascular Diseases. 2025 Jan 20.
4. Maurer LR, Martin ND. Sepsis management of the acute care surgery patient: What you need to know. Journal of Trauma and Acute Care Surgery. 2025 Apr 1;98(4):533-40.
5. Gross CR, Zafirova Z. SHOULDER REPLACEMENT IN PATIENT WHO HADA HEART AND LUNG TRANSPLANT. Perioperative Medicine: A Problem-Based Learning Approach. 2025 Jan 24:195.
6. Provenzano DA, Hanes M, Hunt C, Benzon HT, Grider JS, Cawcutt K, Doshi TL, Hayek S, Hoelzer B, Johnson RL, Kalagara H. ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine. Regional Anesthesia & Pain Medicine. 2025 Jan 20.
7. Gomm L. Readiness to Implement Novel SACT: Tumor-Infiltrating Lymphocyte Therapy. InSeminars in Oncology Nursing 2025 Feb 11 (p. 151841). WB Saunders.
8. Gomm L. Readiness to Implement Novel SACT: Tumor-Infiltrating Lymphocyte Therapy. InSeminars in Oncology Nursing 2025 Feb 11 (p. 151841). WB Saunders.
9. Shook JK, Hutson TE, Singer EA, Ghodoussipour SB. Optimizing Pharmacotherapy During Implementation of Enhanced Recovery After Surgery (ERAS) in Ambulatory Urologic Oncology Surgery: Narrative Review. Cancers. 2025 Feb 11;17(4):614.
10. Witten JC, Elgharably H, Martin DR, Apte SS. Basic Science Aspects of the Pathogenesis of Infective Endocarditis. InInfective Endocarditis: A Multidisciplinary Team Approach to a Complex Disease 2025 Feb 25 (pp. 59-73). Cham: Springer Nature Switzerland.
11. Moheb N, Mohamed AF, Elbaghdady KZ, Saeed AM, Abu-Elghait M. Monitoring and controlling bacteria in cleanrooms of pharmaceutical plant model: an in vitro study. Environmental Monitoring and Assessment. 2025 Jan;197(1):1-8.
12. Elneihoum A, Ehmaid M, Alrabte H, Makraz I, Mangoush O, Darrat Y, Abonowara A, Bugila A, Smer A. Abstracts of the 10th Libyan Cardiac Society Congress, October 10–13, 2024, Misrata, Libya. Ibnosina Journal of Medicine and Biomedical Sciences. 2025 Mar 3.
13. Starshinova AA, Savchenko AA, Borisov A, Kudryavtsev I, Rubinstein A, Dovgalyuk I, Kulpina A, Churilov LP, Sobolevskaia P, Fedotkina T, Kudlay D. Immunological Disorders: Gradations and the Current Approach in Laboratory Diagnostics. Pathophysiology. 2025 Apr 18;32(2):17.
14. Arslan Ü, Yıldız Z, Pir İ, Aykut Ç. The Justification of Open Surgical Repair for an Abdominal Aortic Aneurysm: A Retrospective Comparison of Outcomes of Endovascular Aneurysm Repair and a Brief Review of the Literature. Life. 2025 Mar 8;15(3):426.
15. Karthik NV, Rally S, Sharma A, Sethi J, Kajal K. COVID-19 Infection in Simultaneous Pancreatic Kidney Transplant Recipients: Case Series and Literature Review. Indian Journal of Transplantation. 2025 Jan 1;19(1):64-9.
16. Busch RA, Katz J, Stephens KR, Collier B. Preoperative Parenteral Nutrition Optimization in Acute Care Surgery Patients: Is it Worth the Wait?. Current Surgery Reports. 2025 Feb 5;13(1):10.
17. Kim EY. Extracorporeal Blood Purification Treatments for Refractory Septic Shock Following Surgery. Journal of Acute Care Surgery. 2025;15(1):5-12.
18. LeBlanc L, Touati D, Lévesque S, Marouan S, Fortin C, Pépin J, Maya C, Bourque C. Syphilitic bi-valvular endocarditis and myocarditis: modern tools applied to long-forgotten complications of a re-emerging disease. The Lancet Infectious Diseases. 2025 Jan 17.
19. Faliouni H, Zaimi A, Fihri Y, Laktib N, Faid S, Britel D, Lakhal Z, Benyass A. Fungal Endocarditis in Pregnancy: A Rare and Fatal Clinical Challenge. Sch J Med Case Rep. 2025 Jan;1:73-5.
20. Klimas F, Zatłoka-Mazur D, Rusiński K, Zając P, Pawłowski B, Sienkiewicz M, Potoczek A, Zięba Z, Pudełko I. Fungal Infections: Epidemiology, Clinical Challenges, and Advances in Diagnosis and Treatment-a review. Quality in Sport. 2025 Feb 17;38:57928-.
21. Ebrahimi P, Taheri H, Bahiraie P, Rader F, Siegel RJ, Mandegar MH, Hosseini K, Shahid F. Incidence of secondary pericardial effusions associated with different etiologies: a comprehensive review of literature. Journal of Cardiothoracic Surgery. 2025 Feb 22;20(1):141.
22. Reis CS, Dias F, Granja B, Matos MI, Ribeiro A, Friões F. Severe Mitral Regurgitation–Induced Acute Heart Failure due to Nonbacterial Thrombotic Endocarditis in a Patient With Urothelial Carcinoma Recurrence. Case Reports in Oncological Medicine. 2025;2025(1):9938933.
23. Mohammadi MR, Mohabbati Mobarez A, Broumand MA, Baseri N, Latifian M, Esmaeili S. Molecular diagnosis of infective endocarditis from culture-negative valve samples in a tertiary hospital in Iran. Microbiology Spectrum. 2025 Jan 31:e01856-24.
24. Blackstone EH. Natural History and Evolution of Treatment of Infective Endocarditis. InInfective Endocarditis: A Multidisciplinary Team Approach to a Complex Disease 2025 Feb 25 (pp. 5-17). Cham: Springer Nature Switzerland.
25. Pacheco SO, Izéria FZ, Ataide CF, de Santana AP, Pereira EL, de Souza Moreno A, Tavernard MR, Ramos SN, Gomes MP, de Souza BM, de Souza VM. ACTING ON COMPLICATIONS IN HEART VALVE REPLACEMENT IN RHEUMATIC FEVER, MINIMIZING RISKS AND GUARANTEEING THE PATIENT'S WELL-BEING: A NARRATIVE REVIEW. Brazilian Journal of Implantology and Health Sciences. 2025 Feb 24;7(2):2536-47.
26. Suura SR. Integrating Artificial Intelligence, Machine Learning, and Big Data with Genetic Testing and Genomic Medicine to Enable Earlier, Personalized Health Interventions. Deep Science Publishing; 2025 Apr 13.
27. Lodhi A, Jindal A, Tomar D, Kumar A, Sharma K. Artificial Intelligence in Nanocarrier Design and Drug Delivery via Nanorobotics-Based Personalised Medicine for Cancer Diagnostics and Therapy. InGenerative Intelligence in Healthcare 2025 Apr 10 (pp. 91-124). CRC Press.
28. Speziale P, Foster TJ, Arciola CR. The endothelium at the interface between tissues and Staphylococcus aureus in the bloodstream. Clinical Microbiology Reviews. 2025 Jan 14:e00098-24.
29. Guo, Y., Yang, P., Wu, Z., Zhang, S. and You, F., 2025. Mechanisms of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao (huang qi) and Angelica sinensis (Oliv.) Diels (dang gui) in Ameliorating Hypoxia and Angiogenesis to Delay Pulmonary Nodule Malignant Transformation. *Integrative Cancer Therapies*, *24*, p.15347354241311917.
30. Choudhury PJ, Navya VB, Jena S, Somu P, Rajkumar S, Das M, Kumar R. Biological Response to Biomaterials. InSmart Ways of Biomaterial Designing Synthesis and Characterization 2025 Mar 7 (pp. 209-228). CRC Press.
31. Shi D, Li Y, Tian M, Xue M, Wang J, An H. Nanomaterials Based Drug Delivery Systems for Therapeutic Applications in Osteoporosis. Advanced Biology.:2400721.
32. Pujol Vallverdú RM, Bagot M, Burg G, De Masson A, Dobos G, Giménez-Arnau AM, Girolomoni G, Gisondi P, Gollnick H, Hannula-Jouppi K, Maurelli M. Special Conditions, Symptoms, and Syndromes. InDermatology Cyberderm WebBook 2025 May 2 (pp. 633-686). Cham: Springer Nature Switzerland.
33. Novák J, Takács T, Tilajka Á, László L, Oravecz O, Farkas E, Than NG, Buday L, Balogh A, Vas V. The sweet and the bitter sides of galectin-1 in immunity: its role in immune cell functions, apoptosis, and immunotherapies for cancer with a focus on T cells. InSeminars in Immunopathology 2025 Dec (Vol. 47, No. 1, pp. 1-21). Springer Berlin Heidelberg.
34. Barik M, Bajpai M, Samantaray JC, Malhotra AK, Das SN, Dwivedi SN. ECounseling For Pre-Conception And Prevention Of Neural Tube Defects, Epilepsy, Congenital Anomalies And Craniosynostosis Diseases Among Asian Indian Population. Neurorehabilitation From Neurotechnologies To Community Care. 10; 10th World Congress Wcnr: 10th World Congress Wcnr
35. Barik M, Singh R. Is It Possible To Completely Save From Suicide Or Attempt To Suicide In Our Society: A Comparetive Study Including With Review Of Literature. Neurorehabilitation From Neurotechnologies To Community Care. 10; 10th World Congress Wcnr: 10th World Congress Wcnr.
36. Barik M.Gene environment interactions in craniosynostosis : A Cohort population study. SOUVENIR. Health and Air Pollution 2018; (1), 70.
37. Barik M. Patnaik S. Environmental blindness awareness and smoking-related diseases (SRDs) and its impact on motivation for smoking cessation in Asian Indian eye patients. SOUVENIR. Health and Air Pollution 2018, (1), 65-66
38. Barik M, Kumar A, Mishra PR, Kapoor PM. Role of MicroRNA in cardiac anesthesia: An innovative consequences and new possibility. Annals of Cardiac Anaesthesia. 2017 Apr 1;20(2):274-5.
39. BARIK M, MEHER SK. Role of Systems Biology in Starvation and Anti-ageing for Public Health Using an Algorithm of Computational Biology and Molecular Medicine.
40. Dadhich A, Choudhary A, Bhardwaj P, Kumar A, Barik M. RECENT TREATMENT MODALITIES OF SARS-COV-2: NEED TO IMPROVE.
41. Verma AK, Barik M. Immunological, Pharmacological, Pharmacokinetics, Therapeutic Targets and Various Therapy for SARS-CoV-2: Recent Advancement and Future Prospective. Acta Scientific Pharmaceutical Sciences. 2021;5:110-43.
42. Ismail M, Verma AK, Abdulkadir A, Kumar A, Dhawan DK, Bolya K, Barik M. Possible mechanical transmission of SARS-CoV-2 causing COVID-19 by insects: infection, prevention, implications, and control. Open Journal of Medical Microbiology. 2020 May 11;10(2):89-101.
43. Verma, A.K., Ahmed, S.F., Hossain, M.S., Bhojiya, A.A., Mathur, A., Upadhyay, S.K., Srivastava, A.K., Vishvakarma, N.K., Barik, M., Rahaman, M.M. and Bahadur, N.M., 2022. Molecular docking and simulation studies of flavonoid compounds against PBP-2a of methicillin-resistant Staphylococcus aureus. *Journal of Biomolecular Structure and Dynamics*, *40*(21), pp.10561-10577.
44. Mishra PR, Barik M, Mahapatra AK. Molecular genetics involved in neural tube defects: recent advances and future prospective for molecular medicine. Neurology India. 2020 Sep 1;68(5):1144-50.
45. BARIK M, BAJPAI M, MALHOTRA A, SAMANTARAY J, DWIEDI S. Gene Therapy in Correcting Birth Defects and Neurological Disorders.
46. Prasad PV, Kumar A, Ansari ZA, Purkayastha K, Kumari M, Barik M. Regenerative medicine: a new dawn for male reproductive issues.Adv Tissue Eng Regen Med Open Access. 2017; 3(1):290–294.
47. Barik M, Dash S, Kumar A. Development of Vaccines for SARS-CoV-2: Recent Advances and Future Prospective.
48. BARIK M, BAJPAI M, MALHOTRA A, SAMANTARAY J, DWIEDI S. Gene Therapy in Correcting Birth Defects and Neurological Disorders.
49. Barik M.. Starvation Stress Induced Cardiac Diseases (Ssicds) and Activity of the Hepatic Enzymes: An Innovative Invention through Experimental Conditions. Adv Res GastroenteroHepatol 2018; 9(4): 555769.
50. Prasad PV, Purkayastha K, Sharma U, Barik M. pH-Sensitive Nanomedicine for Treating Gynaecological Cancers. JWRH.2020;2:35-50.
51. Mishra PR, Chawla V, Patnaik SK, Kumar A, Barik M. Organ Transplant Infections In India: Recent Advances And Future Prospectives. Ijsrm/Human4/4-20.
52. AlOthman O, Bobat S. Comparison of the short and long-term outcomes of endovascular repair and open surgical repair in the treatment of unruptured abdominal aortic aneurysms: meta-analysis and systematic review. Cureus. 2020 Aug 12;12(8).
53. Katzen BT, Dake MD, MacLean AA, Wang DS. Endovascular repair of abdominal and thoracic aortic aneurysms. Circulation. 2005 Sep 13;112(11):1663-75.
54. Arslan Ü, Yıldız Z, Pir İ, Aykut Ç. The Justification of Open Surgical Repair for an Abdominal Aortic Aneurysm: A Retrospective Comparison of Outcomes of

Endovascular Aneurysm Repair and a Brief Review of the Literature. Life. 2025 Mar 8;15(3):426.
55. Barik M, Mallik KC, Biswas S. "Strengthening the Health Care System (HCS)in Jaharkhand State at the Primary, Secondary and Tertiary Health Care Level: Need to be Revisilent".Acta Scientific Medical Sciences.2020; 4.6:28-31.
56. Mishra PR, Chawla V, Patnaik SK, Kumar A, Barik M. Organ Transplant Infections In India: Recent Advances And Future Prospectives. Ijsrm/Human4/4-20.
57. Elkouri S, Gloviczki P, McKusick MA, Panneton JM, Andrews J, Bower TC, Noel AA, Harmsen WS, Hoskin TL, Cherry K. Perioperative complications and early outcome after endovascular and open surgical repair of abdominal aortic aneurysms. Journal of vascular surgery. 2004 Mar 1;39(3):497-505.
58. Nordon IM, Karthikesalingam A, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Secondary interventions following endovascular aneurysm repair (EVAR) and the enduring value of graft surveillance. European Journal of Vascular and Endovascular Surgery. 2010 May 1;39(5):547-54.
59. Patel R, Sweeting MJ, Powell JT, Greenhalgh RM. Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1): a randomised controlled trial. The Lancet. 2016 Nov 12;388(10058):2366-74.
60. Mehta M, Sternbach Y, Taggert JB, Kreienberg PB, Roddy SP, Paty PS, Ozsvath KJ, Darling III RC. Long-term outcomes of secondary procedures after endovascular aneurysm repair. Journal of vascular surgery. 2010 Dec 1;52(6):1442-9.
61. Laheij RJ, Buth J, Harris PL, Moll FL, Stelter WJ, Verhoeven EL. Need for secondary interventions after endovascular repair of abdominal aortic aneurysms. Intermediate-term follow-up results of a European collaborative registry (EUROSTAR). Journal of British Surgery. 2000 Dec;87(12):1666-73.
62. Scicolone R, Paraskevas KI, Argiolas G, Balestrieri A, Siotto P, Suri JS, Porcu M, Mantini C, Caulo M, Masala S, Cademartiri F. Atherosclerotic Abdominal Aortic Aneurysms on Computed Tomography Angiography: A Narrative Review on Spectrum of Findings, Structured Reporting, Treatment, Secondary Complications and Differential Diagnosis. Diagnostics. 2025 Mar 12;15(6):706.
63. Van Nut L, Duc NH, AlMosa AS, Huy NT, Tin LD. Overcoming Anatomical Constraints: A Case of Successful Endovascular Repair in a High-Risk Patient With a Short, Angulated Abdominal Aortic Aneurysm. Cureus. 2025 Feb 13;17(2).
64. Barik M and Verma AK. "Home Made Herbal Sanitizer (HHS), Homemade Potential Herbal Medicine (HPHM) May Helpto Fight against Covid-19, SARS-CoV-2 and Boost the Immunity: A Cost-Effectiveness Approach for Common Public". Acta Scientific Medical Sciences 4.11(2020).
65. Barik M**.** (2020). "Prognostic and Diagnostic Value of COVID-19". A Text-Book of the COVID- SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
66. **Barik M** (2020) "Guidelines and Protocol Development for Molecular Targeted Therapy (MMT) for COVID-19 Patients". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
67. **Verma AK, Kumar A, Barik M** (2020) "Aarogya Setu App (APA) for COVID-19: Recent Advances and Future prospective" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
68. **Lone ZA, Verma AK, Barik M**(2020) "Guidelines and Protocol Development for Molecular Targeted Therapy (MMT) for COVID-19 Patients". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development.Mahi International Publisher, Ahmadabad, India.
69. **Lawal M, Verma AK, Lawan NY, Barik M (2020).** "Prognostic and Diagnostic Value of COVID-19". A Text-Book of the COVID- SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
70. **Kumar A, Verma AK, Barik M (2020)"** Screening and Diagnosis of SARS-CoV-2: Need of the hour". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
71. Umar B, Lawal M, Verma AK**,** Labaran AN, **Barik M** (2020) "Diagnostic Test Kit for COVID-19". A Text-Book of the COVID- SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
72. **Bashir S, Lone ZA, Verma AK, Barik M(2020)** "Correlation of Hepatitis A, B, C Emphasis with COVID-19: Recent Advances and Future Prospective" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
73. **Shuaibu BS, Hamza UA, Verma AK, Barik M** (2020)" Challenges for COVID-19, SARS- 2, Influenza, HIN1 Development of Vaccine and Way Forward". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
74. **Umar Na'abba Z, Umar B, Verma AK, Barik M (2020)** "Prophylaxis Regimens of COVID-19 and SARS-2: Recent Advance and Future Prospective". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
75. **Lone ZA, Dixit S, Verma AK, Ahmad Dar B, Khan ZA, Barik M (2020)** "Future challenges for COVID 19". A Text- Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
76. **Sanadhya KS, Ranawat MK, Verma AK, Barik M (2020)** "SARS-CoV-2, Mode of Transmission and Treatment Modalities: A Unique Guidelines". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
77. **Raghav JS, Sharma SK, Verma AK, Barik M (2020).** "Mathematical Analysis and Interpretation of lockdown success in India for the prevention of COVID-19 till vaccination". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
78. **Yakub AU, Abubakar MU, Garba MA, Verma AK, Barik M** (2020), "Aetiopathogenesis, Causal Factor and Morphology of COVID – 19: Recent Advances and Future Prospective". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
79. **Bashir S, Lone ZA, Verma AK, and Barik M(2020)** "Immunopathogenecity in COVID-19" Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
80. **Shitu MK, BabaHH, Verma AK, Barik M (2020)** "Impact of SARS-CoV-2 in the World: Recent Advances and Future Prospective" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
81. **Barik M, Dash S, Verma AK (2020).** "Vaccines for COV- SARS-2: Recent Advances and Future Prospective" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India.
82. **Dadhich A, Choudhary A, Bhardwaj P, Verma AK, Barik M (2020)** "Recent Treatment Modalities of SARS-CoV-2: Need to Improve" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
83. **Adam MA, Usman ZA, Umar B, Lawal M, Balarabe BA, Verma AK, Barik M (2020)** "Elementary Idea of COVID-19: A Basic Concept" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
84. **Balarabe BA, Umar AM, Yakub UA, Garba MA, Verma AK, Barik M (2020)** "History of COVID-19: An Update"A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
85. **Usman ZA, Adam MA, Umar B, Lawal M, Balarabe BA, Verma AK, Barik M(2020)** " Sanitizer and Cleaning for COVID-19: Principles, Guidelines and Prospective" A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
86. **Lawan NY, Muhammad II, Lawal M, Verma AK,Venkata V.P.R.P., and Barik M (2020)** Online Education during COVID-19 Periods. A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
87. **Ismal RA, Mustapha MB, Bala HA, Boliya K, Verma AK, Teli PK, Barik M (2020)** Novel invention and guidelines and protocol development for SARS-CoV-2: Present, Past and Future"A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher Ahmadabad, India
88. **Verma AK, KumarA, Dhawan DK, Barik M.** "Smart Decision for Smart Time Application for Fight Against SARS-CoV-2 Through Aarogya Setu App (APA): A Study, ActaScientific Medical Sciences (In Press)
89. **Kumar A, Verma AK, Barik M**. Recent 19 treatment Modalities of SARS-CoV-2: Need to Improve. *Acta Scientific Microbiology* Manuscript Id-ASMI-20-RW-209.
90. **Mishra Sk, Barik M.** Impact of Mucormycosis on the human eye.The Indian Optician.2021.53;308:110-111.
91. Barik M**.** (2020). "Prognostic and Diagnostic Value of COVID-19". A Text-Book of the COVID- SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
92. Kapoor PM,Barik M**,** Bhardwaj V, Taneja S, SethiBS.Recent Advances in Cardiopulmonary Resuscitation from 2010 to 2015. Clinical Simulation inMedicine (For all Examinations in Cardiology, Critical Care, Anesthesia and Pulmonary Medicine).2016;1:272-297.
93. Barik M**,**Bajpai M, Das RR, Panda SS. Study of environmental and genetic factors in children with craniosynostosis: A case-control study. J PediatrNeurosci. 2013; 8:89–92.
94. Barik M. Starvation Stress Induced Cardiac Diseases (Ssicds) and Activity of the Hepatic Enzymes: An Innovative Inventionthrough Experimental Conditions. Adv Res GastroenteroHepatol 2018; 9(4): 555769.
95. Barik M **et al.** Role of MicroRNA in Cardiac Anaesthesia: An Innovative Consequences and New Posibility. Anals of Cardiac Anaesthesia.2017;20 (2):1-2.
96. **Barik M.** Metabolic Consequence of Short Term Starvation in Gastrointestinal Diseases: A Mini Review.Adv Res Gastroentero Hepatol.2017;3: 55561**17.**
97. **Barik M,**Mallik KC, Biswas S. "Strengthening the Health Care System (HCS) in Jaharkhand State at the Primary, Secondary and Tertiary Health Care Level: Need to be Revisilent".Acta Scientific Medical Sciences.2020; 4.6:28-31.
98. **Barik M** (2020) "Guidelines and Protocol Development for Molecular Targeted Therapy (MMT) for COVID-19 Patients". A Text-Book of the COVID-SARS-2: Guidelines and Protocol Development. Mahi International Publisher, Ahmadabad, India.
99. **Barik M.** Role of Starvation in Human Body Metabolism and Its Effect on Tissue Specific. International Journal of Medical Toxicology & Legal Medicine.2015; 18:31-35.
100. **Barik M,** Kumar A, Rathore P, Kumar A, Kumawat G, Kumar V, KanaugiaRR.Recentadvances Application in Diffuse Axonal Injury Imaging (Daii) and Future Prospective: A Comparative Study with Systematic Review of literature.Journal of Forensic Medicine and Toxicology.2015;32(1):48-53.
101. **Barik M,** Mishra PR, Ray B.Effect of nimodipine on morphine-related withdrawal syndrome in rat model: An observational study.Journal of Pediatric Neurosciences.2017;55(3):56.
102. Patnaik KC**, Barik M**. Effects of cadmium chloride on the ascorbic acid metabolism in tissues of Indian toad,Bufomelanostictus.Nature Environment & Pollution Techonology.2004;8(4):273-279.
103. **Barik M et al.** Effects of cadmium chloride on calcium and phosphorus turn over in the tissues of Bufomelanostictus.J Ecobiol.2006;8(4):371-377.
104. **Barik M,** Bajpai M, Malhotra A, Samantary J, Dweidi SN. Potential therapeutic strategies and its application in correcting birth defects, craniosynostosis, neurological disorders and other diseases. J MetabSyndr. 2013; 2:122.
105. **Barik M,**Meher SK.USA: Studium Press LLC; 2014. Role of Systems Biology in Starvation and Anti-ageing for Public Health Using an Algorithm of Computational Biology and Molecular Medicine. Biotechnology: Applied Synthetic Biology; pp.165-189.
106. **Barik M,**Bajpai M, Malhotra A, Samantaray JC, Dwvedi SN.USA: Studium Press LLC; 2014.Gene Therapy in Correcting Birth Defects and Neurological Disorders. Biotechnology, gene and protein engineering; pp. 149–158.
107. Mishra P R, Mohakud S, **Barik M.** A Comparison between Medical and Non- Medical Students in India for Cadaveric Organ Donation (COD): A Questionnaire Based Study.Journal of Forensic Medicine and Toxicology.2016; 33 (1):12-15.
108. **Barik M,** Mishra PR, Rathore P, Rajnish R, Ranjan,KumarA,Agarwal D, MohakudS,Kumawat R. CADAVERIC ORGAN DONATION (COD): WHERE WE STAND FOR?International Journal of Current Research.2016;8(6):32918- 32921.
109. **Barik M,** Meher S, Chaudhary V. Current Prospective in Gene Therapy and the Role Played by Medical Informatics.Indian Journal of Medical Informatics.2012;6 (1): 51 - 66.
110. **Barik M,** Meher S. Evaluation and Monitoring of Meta-Analysis in Medical Research through Information Technology.Indian Journal of Medical Informatics.2012;6 (1): 51 - 66.
111. **Barik M et al.** Diffuse axonal injury imaging (daii) and future prospective: a comparative study with recent advances application in systematic review of literature. International Journal of Current Research.2016;8(3):28440-28445.
112. **Barik M.** Age-related muscles biochemical information and behavioural changes through dietary supplementation and restriction through stress condition.Clinical Epidemiology Unit, AIIMS,New Delhi,India.BMJ.2012;1 (1):122.
113. **Barik M.** Cryopreservation technology is an effective tool for clinical application and research. Clinical Epidemiology Unit, AIIMS,NewDelhi,India. BMJ.2012;1 (1):81.
114. Prusti JS, Mishra PR, Baa J,Mohakud S, **Barik M**. IMAGING MODALITIES ON FEMORAL NECK ANTEVERSION (FNA): RECENT ADVANCES AND FUTURE PROSPECTIVE.International Journal of Current Research.2016;8(6):32553- 32556.
115. **Barik M.** Diagnostic application of 99mTc ethyl cysteinate dimer single photon emission computed tomography (99mTc ECD SPECT) on craniosynostosis children in India: A prospective study.Proceedings of the 8th Asia Pacific Association for Medical Informatics New Delhi.Indian Association of Medical Informatics.2014;8(8):138.
116. **Barik M,** Meher S. RECENT ADVANCES OF METAGENOMICS, MEDICALINFORMATICS AND NEXT GENERATION SEQUENCING (NGS): AN UP-TO-DATE OBSERVATION OF MEDIAL THERAPEUTICS & CLINICAL PRACTICE. 9 th IAMI Biennial Conference. Indian Association of Medical Informatics.2014;9 (9):31.
117. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention

of acute rejection. The Lancet. 1995 May 27;345(8961):1321-5.
118. Afzal K, Bagga A, Menon S, Hari P, Jordan SC. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatric Nephrology. 2007 Dec;22:2059-65.
119. Shapiro R, Jordan ML, Scantlebury VP, Vivas C, Marsh JW, McCauley J, Johnston J, Randhawa P, Irish W, Gritsch HA, Naraghi R. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999 Feb 15;67(3):411-5.
120. Arshad H, Yasrab M, Blanco A, Birkness-Gartman JE, Fishman EK. Mycophenolate-associated colitis in an orthotopic heart transplant patient-an unusual case presentation. Radiology Case Reports. 2025 Apr 1;20(4):1822-6.
121. Bratu A, Cirstoiu C, Popa MI, Popescu M, Dumitrascu OC, Agapie M, Orban C. Critical Management of Septic Orthopedic Patients: The Impact of Intensive Care on Survival and Recovery. Life. 2025 Apr 21;15(4):674.
122. Shappell CN, Yu T, Klompas M, Agan AA, DelloStritto L, Faine BA, Filbin MR, Mohr NM, Park ST, Plechot K, Porter E. Frequency of Antibiotic Overtreatment and Associated Harms in Patients Presenting With Suspected Sepsis to the Emergency Department: A Retrospective Cohort Study. Clinical infectious diseases. 2025 Apr 15:ciaf118.
123. Malinowska A, Dębska-Ślizień A. Graft function in kidney transplant recipients after COVID-19: a brief review. InRenal Disease and Transplantation Forum 2024 (Vol. 17, No. 1, pp. 11-18).
124. AU EH, WEBSTER AC, CHAPMAN JR. 4 The Recipient of. Kidney Transplantation-E-Book: Principles and Practice. 2024 Nov 27:55.
125. Malinowska A, Dębska-Ślizień A. Graft function in kidney transplant recipients after COVID-19: a brief review. InRenal Disease and Transplantation Forum 2024 (Vol. 17, No. 1, pp. 11-18).
126. Solera JT, Árbol BG, Mittal A, Hall V, Marinelli T, Bahinskaya I, Selzner N, McDonald M, Schiff J, Sidhu A, Humar A. Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023. American Journal of Transplantation. 2024 Jul 1;24(7):1303-16.
127. Chukwu CA. *Epidemiologic Outcomes and Predictors of Outcomes in Kidney Transplant Recipients* (Doctoral dissertation, The University of Manchester (United Kingdom)).
128. AU EH, WEBSTER AC, CHAPMAN JR. 4 The Recipient of. Kidney Transplantation-E-Book: Principles and Practice. 2024 Nov 27:55.
129. Seaquist ER, Wendt C. Dear Colleagues: Welcome to the 22nd Department of Medicine's Robert P. Hebbel Research Day. This event will showcase 88 abstracts illustrating the best research from our outstanding learners, staff and faculty throughout the Twin Cities. The collective mission of the Department of Medicine is to improve the health and well-being of.
130. Šoić D, Rudman N, Frkatović A, Vučić-Lovrenčić M, Duvnjak L, Pociot F, Gornik O. N-glycosylation of complement component 3 in type 1 diabetes. In20th IDS Congress 2024 Nov.
131. Swiss Association for the Study of the Liver. Supplementum 281: Abstracts of the Annual meeting of the Swiss Society of Gastroenterology, the Swiss Society of Visceral Surgery, the Swiss Association for the Study of the Liver and the Swiss Society of Endoscopy Nurses and Associates. Swiss Medical Weekly. 2024 Sep 9;154(9):4177-.
132. Admasu N, Jihad M, Kebede A, Getnet M. Incidence and predictors of opportunistic infections among HIV-infected children on antiretroviral therapy at public health facilities of Southwest Ethiopia People Regional State, 2023: a multicenter retrospective follow-up study. BMC pediatrics. 2024 Oct 11;24(1):653.
133. Zanet E, Taborelli M, Tirelli U, Diez-Martin J, Balsalobre P, Re A, Rupolo M, Mazzucato M, Cwynarski K, Gomez MR, Guillerm G. Long-Term Clinical Outcomes After Autologous Hematopoietic Stem Cell Transplantation in 49 Individuals Living With HIV (PLWH) and Affected by High-Risk or Relapsed Lymphoma: A European Experience of Continued Relevance for PLWH. Journal of Medical Virology. 2025 Jan;97(1):e70165.
134. Vo LT, Phan DQ, Nguyen PH, Gyan A, Vuong NM, Nguyen TN, Vo LY, Huynh G. Clinical characteristics and treatment outcomes of opportunistic infections in advanced HIV disease patients among men who have sex with men in Vietnam: A prospective cross-sectional study. BMC Infectious Diseases. 2025 Feb 25;25(1):271.
135. Atkinson A, Kraus D, Banholzer N, Miro JM, Reiss P, Kirk O, Mussini C, Morlat P, Podlekareva D, Grant AD, Sabin C. HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983–2015. PloS one. 2024 Oct 25;19(10):e0312035.
136. Wayland J, Teixeira JP, Nielsen ND. Sepsis in 2024: A review. Anaesthesia & Intensive Care Medicine. 2024 Aug 19.
137. Torres JS, Tamayo-Giraldo FJ, Bejarano-Zuleta A, Nati-Castillo HA, Quintero DA, Ospina-Mejía MJ, Salazar-Santoliva C, Suárez-Sangucho I, Ortiz-Prado E, Izquierdo-Condoy JS. Sepsis and post-sepsis syndrome: a multisystem challenge requiring comprehensive care and management—a review. Frontiers in Medicine. 2025 Apr 8;12:1560737.
138. La Via L, Sangiorgio G, Stefani S, Marino A, Nunnari G, Cocuzza S, La Mantia I, Cacopardo B, Stracquadanio S, Spampinato S, Lavalle S. The global burden of sepsis and septic shock. Epidemiologia. 2024 Jul 25;5(3):456-78.
139. Kumar NR, Balraj TA, Kempegowda SN, Prashant A. Multidrug-resistant sepsis: A critical healthcare challenge. Antibiotics. 2024 Jan 4;13(1):46.
140. Tan YY, Ong WT, Liau MY, Shelat VG. Postoperative peritonitis: from early recognition to optimal management in a challenging landscape. GLOBAL INFECTION PREVENTION AND MANAGEMENT IN HEALTHCARE.:363.
141. Ramasco F, Méndez R, Suarez de la Rica A, González de Castro R, Maseda E. Sepsis Stewardship: The puzzle of antibiotic therapy in the context of individualization of decision making. Journal of Personalized Medicine. 2024 Jan 18;14(1):106.
142. Manigrasso J, Desai N, Naoum E. Maternal sepsis: background, diagnosis and management. BJA education. 2024 Nov 1;24(11):389-98.
143. Saxena J, Das S, Kumar A, Sharma A, Sharma L, Kaushik S, Srivastava VK, Siddiqui AJ, Jyoti A. Biomarkers in sepsis. Clinica Chimica Acta. 2024 Jul 26:119891.
144. Matsueda S, Chen L, Li H, Yao H, Yu F. Recent clinical researches and technological development in TIL therapy. Cancer Immunology, Immunotherapy. 2024 Sep 12;73(11):232.
145. Unger JM, McAneny BL, Osarogiagbon RU. Cancer in rural America: Improving access to clinical trials and quality of oncologic care. CA: A Cancer Journal for Clinicians. 2025 Mar 27.
146. Turner L, Taylor S, Ward A, Thistlethwaite F, Yorke J. The Barriers and Enablers to Participation in Oncology Clinical Trials for Ethnically Diverse Communities: A Qualitative Systematic Review Using Metaethnography. Cancer Nursing. 2024 Nov 20:10-97.
147. Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, van de Poll-Franse LV, Massi D, Schadendorf D. Cutaneous melanoma. Nature Reviews Disease Primers. 2025 Apr 3;11(1):23.
148. Loaiza-Bonilla A, Thaker N, Chung C, Parikh RB, Stapleton S, Borkowski P. Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology. American Society of Clinical Oncology Educational Book. 2025 May 2;45(3):e100048.
149. Unger JM, McAneny BL, Osarogiagbon RU. Cancer in rural America: Improving access to clinical trials and quality of oncologic care. CA: A Cancer Journal for Clinicians. 2025 Mar 27.
150. Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, van de Poll-Franse LV, Massi D, Schadendorf D. Cutaneous melanoma. Nature Reviews Disease Primers. 2025 Apr 3;11(1):23.
151. Loaiza-Bonilla A, Thaker N, Chung C, Parikh RB, Stapleton S, Borkowski P. Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology. American Society of Clinical Oncology Educational Book. 2025 May 2;45(3):e100048.
152. Morris ZS, Demaria S, Monjazeb AM, Formenti SC, Weichselbaum RR, Welsh J, Enderling H, Schoenfeld JD, Brody JD, McGee HM, Mondini M. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology. 2025 Mar 1;26(3):e152-70.
153. Kumar V, MeherS, Sharma SS, **Barik M.** Contingency Planning For Downtime Of Hospital Information System: An Implemented Approach In Public Hospital.Proceedings of the 8th Asia Pacific Association for Medical Informatics.Indian Association of Medical Informatics.2014;8 (8):181.
154. Kumbham S, Md Mahabubur Rahman K, Foster BA, You Y. A Comprehensive Review of Current Approaches in Bladder Cancer Treatment. ACS Pharmacology & Translational Science. 2025 Jan 6;8(2):286-307.
155. Kumbham S, Md Mahabubur Rahman K, Foster BA, You Y. A Comprehensive Review of Current Approaches in Bladder Cancer Treatment. ACS Pharmacology & Translational Science. 2025 Jan 6;8(2):286-307.
156. Huang HH, Cheng PY, Tsai CY. Exploring artificial intelligence in functional urology: A comprehensive review. Urological Science. 2025 Mar 1;36(1):2-10.
157. Toshib GA, Aggarwal N, Panaiyadiyan S, Jain S. GG01-22 RENAL HYDATID DISEASE: SPECTRUM OF PRESENTATION, DIAGNOSTIC AND TREATMENT OPTIONS AND OUR EXPERIENCE. Journal of Urology. 2025 May 1;213(5S):e72.
158. Nigro N, Shahinyan G, Lin S, Bhalla RG, Flynn BJ. A comprehensive review of urinary tract fistulas: the evolution of etiologies, surgical techniques, and contemporary outcomes. Therapeutic Advances in Urology. 2025 Feb;17:17562872251317344.
159. Mi G, Ma Y, Liu L, Liao B, Wang K. Optimal energy source selection strategies for en bloc resection in non-muscle invasive bladder cancer: a systematic review and network meta-analysis. World Journal of Urology. 2025 Mar 10;43(1):155.
160. Vass C, Pinto CA, Myers K, Imai K, Bussberg C, Bhattacharya R, Calhoun SR, Poulos C. Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment. Future Oncology. 2025 Feb 15:1-0.
161. Sanders JN. *Phenomenological Qualitative Study: Exploring Strategies for Facilitating Technology Adoption Among Veteran Educators* (Doctoral dissertation, National University).
162. Hillman AP. *A Systems-Theoretic Approach to Design of Early Concepts for Novel, Complex Systems in Aerospace* (Doctoral dissertation, Massachusetts Institute of Technology).
163. Lematta G, Chiou EK, Cooke NJ, Amazeen PG, Holder E. Adopting Human-Machine Teaming Assessment in Test and Evaluation for Defense Acquisition: Social Challenges Despite Technical Capability.
164. Hatch-Tocaimaza DK, Abrica EJ, Rios-Aguilar C. Justice, Sustainability, and Disrupting Campus Climate Studies Toward More Just Climate Futures of Higher Education. InHigher Education: Handbook of Theory and Research: Volume 40 2025 Jan 31 (pp. 177-263). Cham: Springer Nature Switzerland.
165. Ogutu CO. Pandemics Do Happen. After COVID-19, How Prepared Are You for the Next One?: The Importance of Business Continuity. Crisis Intel, Llc; 2025 Apr 28.
166. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Medical preparedness for bioterrorism and chemical warfare: A public health integration review. Medicine. 2025 May 2;104(18):e42289.
167. Lin D, Chen W, Lin Z, Liu L, Zhang M, Yang H, Liu Z, Chen L. Viral Transmission in Sea Food Systems: Strategies for Control and Emerging Challenges. Foods. 2025 Mar 20;14(6):1071.
168. Saha A, Ghosh Roy S, Dwivedi R, Tripathi P, Kumar K, Nambiar SM, Pathak R. Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern. Vaccines. 2025 Apr 17;13(4):424.
169. Hellberg R, Sprängare D, Candell O, Carpenfelt C, Lundberg K, Samuelsson P, Antai I, Andersson P, Backlund L. Performance constraints in defence industry supply chains: evidence from case studies. Defence and Peace Economics. 2025 May 9:1-36.
170. Wang C, Zhao Y, Mu D, Zhang X, Li T, Kong H, Pu D. Epidemiological characteristics of respiratory pathogens in Changchun, Jilin Province, China, following the pandemic. International Journal of Environmental Health Research. 2025 Apr 4:1-0.
171. Fatima M, An T, Park PG, Hong KJ. Advancements and Challenges in Addressing Zoonotic Viral Infections with Epidemic and Pandemic Threats. Viruses. 2025 Feb 28;17(3):352.